Work

672P Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results on efficacy and correlative analysis

Year: 2022

Type: article

Abstract: Immune checkpoint inhibitors are standard of care in recurrent/metastatic SCCHN. We evaluated concurrent radioimmunotherapy (RIT) with Nivo and Ipi in the definitive setting for patients with high-risk LA SCCHN.

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.796

Authors: I. Vathiotis, J.M. Johnson, L. Harshyne, A. Luginbuhl, J.M. Curry, D. Cognetti, R. Axelrod, V. Bar-Ad, A. Argiris

Institutions: Thomas Jefferson University, Sidney Kimmel Cancer Center, Hygeia Hospital

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,230

OpenAlex ID: W4295817701

FWCI: 0.592

Cites:

Cited by: 3

Related to: 10